Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
Our pipeline comprises multiple product candidates for infectious diseases and cancer. Many of our programs are supported by external funding through either private or governmental partnerships.
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Bavarian Nordic offers a challenging international working environment in which job satisfaction and personal growth have a high priority.
Leveraging our unique and versatile discovery platform, our scientists are focused on bringing new and safer vaccines to the market
MVA-BN® is the platform for IMVANEX®, an approved vaccine in Europe, and the poxvirus platform has been studied extensively for cancer treatment
We have built a revenue-generating biotech company with a late stage pipeline in blockbuster markets, strong IP, and manufacturing expertise